Literature DB >> 10942106

Exclusion of NFIL3 as the gene causing hereditary sensory neuropathy type I by mutation analysis.

D J Hulme1, I P Blair, J L Dawkins, G A Nicholson.   

Abstract

Hereditary sensory neuropathy type I (HSN-I) is an autosomal dominant peripheral neuropathy affecting sensory and motor neurons. The disease involves distal sensory loss, distal muscle wasting and weakness, and variable neural deafness. The HSN1 locus has been mapped to a genetic interval of 3-4 cM on chromosome 9q22.1-q22.3 and is flanked by markers D9S1781 and FB19B7. This interval contains the gene NFIL3, a transcription factor that is regulated by the cytokine IL-3. Northern blot analysis of NFIL3 showed a ubiquitously expressed 2.2-kb mRNA. Expression was highest in the lung, with lower levels of expression in the brain and spinal cord. Mutation analysis by direct sequencing of reverse transcription/polymerase chain reaction products from HSN-I patients excluded the coding region of the NFIL3 from being involved in the pathogenesis of HSN-I.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10942106     DOI: 10.1007/s004390000306

Source DB:  PubMed          Journal:  Hum Genet        ISSN: 0340-6717            Impact factor:   4.132


  3 in total

1.  IL-4-induced transcription factor NFIL3/E4BP4 controls IgE class switching.

Authors:  Masaki Kashiwada; Deborah M Levy; Lisa McKeag; Keri Murray; Andreas J Schröder; Stephen M Canfield; Geri Traver; Paul B Rothman
Journal:  Proc Natl Acad Sci U S A       Date:  2009-12-22       Impact factor: 11.205

2.  A systems biology approach to identify intelligence quotient score-related genomic regions, and pathways relevant to potential therapeutic treatments.

Authors:  Min Zhao; Lei Kong; Hong Qu
Journal:  Sci Rep       Date:  2014-02-25       Impact factor: 4.379

3.  New Frontiers for the NFIL3 bZIP Transcription Factor in Cancer, Metabolism and Beyond.

Authors:  Megan Keniry; Robert K Dearth; Michael Persans; Ramon Parsons
Journal:  Discoveries (Craiova)       Date:  2014 Apr-Jun
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.